Want to see JP:7730 full AI Analyst Report?
7730 Stock Chart & Stats
¥1500.50
¥30.00(1.62%)
At close: 4:00 PM EST
¥1500.50
¥30.00(1.62%)
Day’s Range― - ―
52-Week Range¥1,199.50 - ¥1,955.00
Previous CloseN/A
Volume546.10K
Average Volume (3M)283.94K
Market Cap
¥155.66B
Enterprise Value¥148.87K
Total Cash (Recent Filing)¥22.84B
Total Debt (Recent Filing)¥64.00M
Price to Earnings (P/E)24.6
Beta1.01
Next Earnings
Oct 14, 2026EPS Estimate
20.52Next Dividend Ex-DateN/A
Dividend Yield2.73%
Share Statistics
EPS (TTM)64.21
Shares Outstanding107,003,280
10 Day Avg. Volume284,170
30 Day Avg. Volume283,943
Financial Highlights & Ratios
PEG Ratio-1.02
Price to Book (P/B)2.31
Price to Sales (P/S)4.12
P/FCF Ratio201.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)74.49
Revenue Forecast (FY)¥33.31B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a rising equity base materially reduce solvency and refinancing risk, giving management durable optionality. Over the next 2–6 months this balance sheet supports capital allocation flexibility for M&A, R&D, or sustaining dividends without stressing liquidity.
High Gross And Operating MarginsSustained high gross and EBIT margins reflect strong product mix, pricing power, and efficient manufacturing in the medical/dental niche. These durable margins provide the structural ability to fund innovation and absorb cost shocks, supporting profitability stability beyond short-term cycles.
Recurring Consumables RevenueA business driven by consumable, repeat-use products creates predictable, recurring revenue and customer stickiness. This structural demand pattern supports steady top-line visibility and helps smooth revenue volatility, undergirding long-term cash generation and sales planning.
Bears Say
Free Cash Flow CompressionA sudden drop in free cash flow limits shareholder-return capacity and internal funding for growth. Even with positive operating cash, volatile FCF suggests heavier capex or working-capital absorption that could constrain dividends, buybacks, or organic expansion over the medium term.
Net Margin DeteriorationDeclining net margin indicates pressures below the operating line—higher SG&A, financing, or other non-operating costs—that erode earnings conversion. If structural, this reduces free cash generation and return on capital, necessitating margin management or structural cost actions to restore profitability.
Slowing Revenue GrowthAfter multi-year expansion, growth decelerated to low single digits in 2025. Slower top-line momentum impairs leverage of fixed costs and limits earnings scalability; absent new product launches or market expansion, this could pressure medium-term return improvement and make investment outcomes more marginal.
7730 FAQ
What was Mani, Inc.’s price range in the past 12 months?
Mani, Inc. lowest stock price was ¥1199.50 and its highest was ¥1955.00 in the past 12 months.
What is Mani, Inc.’s market cap?
Mani, Inc.’s market cap is ¥155.66B.
When is Mani, Inc.’s upcoming earnings report date?
Mani, Inc.’s upcoming earnings report date is Oct 14, 2026 which is in 86 days.
How were Mani, Inc.’s earnings last quarter?
Mani, Inc. released its earnings results on Jul 15, 2026. The company reported ¥17.7 earnings per share for the quarter, missing the consensus estimate of ¥19.98 by -¥2.28.
Is Mani, Inc. overvalued?
According to Wall Street analysts Mani, Inc.’s price is currently Overvalued.
Does Mani, Inc. pay dividends?
Mani, Inc. pays a Semiannually dividend of ¥24 which represents an annual dividend yield of 2.73%. See more information on Mani, Inc. dividends here
What is Mani, Inc.’s EPS estimate?
Mani, Inc.’s EPS estimate is 20.52.
How many shares outstanding does Mani, Inc. have?
Mani, Inc. has 107,003,280 shares outstanding.
What happened to Mani, Inc.’s price movement after its last earnings report?
Mani, Inc. reported an EPS of ¥17.7 in its last earnings report, missing expectations of ¥19.98. Following the earnings report the stock price went down -1.142%.
Which hedge fund is a major shareholder of Mani, Inc.?
Currently, no hedge funds are holding shares in JP:7730
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mani, Inc.
Mani, Inc. engages in the manufacture and supply of surgical and dental instruments in Japan, Asia, Europe, North America, and internationally. The company operates through three segments: Surgical Products, Eyeless Needle Products, and Dental Products. The company offers surgical instruments, such as maniplers, vessel knives, ENT knives, and stainless wire needles; and ophthalmic instruments, including ophthalmic sutures and knives, and trocar kits for vitrectomy. It also provides surgical eyeless, eyed, taper point, cutting, ophthalmic needles; and dental instruments, such as endodontic instruments, endodontic rotary instruments, root canal obturation, diamond and carbide burs, finishing and polishing instruments, sutures and surgical needles, endodontic micro-accessories, and endodontic accessories. Mani, Inc. was founded in 1956 and is headquartered in Utsunomiya, Japan.